enGene Therapeutics Inc. (ENGN) › Shareholders' EquityenGene Therapeutics Inc. (ENGN) — Shareholders' EquityAnnual figures by period end, from SEC filings.2021-10-31: -$53.44M2022-10-31: -$76.61M2023-10-31: $72.49M2024-10-31: $272.61M2025-10-31: $167.71M$167.71M2021-10-31Shareholders' Equity (USD)2025-10-31Period endedShareholders' EquityChange YoYSource filing2025-10-31$167.71M-38.5%2025-12-22Balance as of period end2024-10-31$272.61M+276.1%2025-12-22Balance as of period end2023-10-31$72.49M—2025-12-22Balance as of period end2022-10-31-$76.61M—2024-12-19Balance as of period end2021-10-31-$53.44M—2024-01-29Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)